Extragonadal penile localization of endodermal sinus tumor is rare but has a favorable prognosis when treated with conservative management and chemotherapy. aFP is a useful marker for both diagnosis and follow-up.
Importantly, the therapeutic effects of HA-Wm were abolished in Fpr2-deficient mice, confirming an FPR2-dependent mechanism of action. Collectively, these results demonstrate that topical treatment of HA-Wm alleviates skin fibrosis and inflammation via an FPR2-dependent pathway, representing a promising noninvasive therapeutic avenue for fibrotic skin disorders such as systemic sclerosis.
Using DDX41 knockout (KO) cells, we found that these cells were sensitive to bleomycin, camptothecin, and UV...Moreover, increased and prolonged RPA and reduced RAD51 foci were found in DDX41 KO and DDX41-R525H expressing cells, indicating a defect in the transition from end resection to RAD51 filament assembly. Overall, our results suggest that DDX41 utilizes its unwinding activity to resolve R-loops, which may play a key role in HR-based repair, and dysregulation of this pathway may lead to MDS/AML.
Further, treatment of mice with bleomycin-induced lung injury using CSP7, an anti-IL-17A antibody, or an IL-17RA blocking antibody attenuates total lung hydroxyproline and soluble collagen content, as well as levels of profibrogenic markers. These observations support the role of IL-17A/IL-17RA signaling in lung injury and post-injury remodeling.
26 days ago
Journal
|
TP53 (Tumor protein P53) • CAV1 (Caveolin 1) • IL17A (Interleukin 17A) • IL17RA (Interleukin 17 Receptor A)
AA (50 μg/animal) and LXA4 improved the antioxidant status and upregulated anti-inflammatory and anti-apoptotic genes IκB and Bcl2. These results suggest AA and LXA4 can prevent bleomycin-induced dysfunction of pancreatic β cells.
Increased levels of Gli3 repressor (Gli3-REP) and decreased GSK-3β phosphorylation further confirmed Hedgehog pathway inhibition. In conclusion, the current study provides the first evidence that CAN, CGA, and their combination modulate the Hedgehog pathway, suggesting their potential as novel therapeutic strategies for IPF.
P=N/A, N=10, Enrolling by invitation, Institute of Oncology Ljubljana | Trial completion date: Nov 2025 --> Dec 2026 | Trial primary completion date: Sep 2025 --> Sep 2026
1 month ago
Trial completion date • Trial primary completion date
This study investigates the therapeutic efficacy of sacubitril/valsartan in a bleomycin-induced rat model of pulmonary fibrosis. Additionally, sacubitril/valsartan treatment resulted in a notable reduction in pulmonary levels of transforming growth factor-β (TGF-β), interleukin-6 (IL-6), and tumor necrosis factor-α (TNF-α), indicating attenuation of both fibrotic and inflammatory responses. Collectively, these findings suggest that sacubitril/valsartan mitigates pulmonary fibrosis through modulation of the SNHG-16/miR-455 axis and inhibition of the Notch-2/Smad-3/TGF-β signaling cascade, highlighting its potential as a promising therapeutic strategy for the management of pulmonary fibrosis.